Tuesday, April 30, 2013

Reduced melatonin levels linked to greater diabetes risk - Life Extension Update

›
In continuation of my update on Melatonin .... "Melatonin receptors have been found throughout the body in many tissues...
Monday, April 29, 2013

FDA Approves Invokana to Treat Type 2 Diabetes

›
In continuation of my update on Canagliflozin We know that,  Canagliflozin  ( Invokana ) is drug for the treatment of  type 2 diabete...
Friday, April 26, 2013

Ganetespib Shows Potency Against Lung Cancer

›
In continuation of my update on Ganetespib Ganetespib Shows Potency Against Lung Cancer
Thursday, April 25, 2013

FDA Approves Stivarga for Advanced Gastrointestinal Stromal Tumors

›
In continuation of my update on Stivagra We know that,  Regorafenib  ( BAY 73-4506 , commercial name Stivarga) is an oral multi-kinas...
Wednesday, April 24, 2013

FDA Approves Tecfidera - a New Treatment for Multiple Sclerosis

›
We know that, Dimethyl fumarate  (DMF) is the methyl ester of fumaric acid. DMF was initially recognized as a very effective hypoxic cel...
Tuesday, April 23, 2013

FDA Approves Kadcyla for Late-Stage Breast Cancer

›
We know that,  Trastuzumab emtansine     in the United States,   ado-trastuzumab emtansine , trade name   Kadcyla ) is an antibody-drug co...
Monday, April 22, 2013

Warner Chilcott Announces FDA Approval of New Ulcerative Colitis Product Delzicol

›
We know that,  Mesalazine   , also known as   mesalamine   ( USAN ) or   5-aminosalicylic acid   (5-ASA), is an   anti-inflammatory   drug...
Friday, April 19, 2013

Takeda Receives FDA Approval for Kazano (alogliptin and metformin) for Type 2 Diabetes

›
Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved  Kazano ...
Wednesday, April 17, 2013

FDA Approves Exjade to Remove Excess Iron in Patients with Genetic Blood Disorder

›
In continuation of my update on  Deferasirox We know that,  Deferasirox   (marketed as   Exjade ) is a   rationally-designed   oral...
Tuesday, April 16, 2013

Santarus Receives FDA Approval of Uceris (budesonide) for the Induction of Remission in Patients with Active, Mild to Moderate Ulcerative Colitis

›
In continuation of my update on  Budesonide We know that,  Budesonide   is a   glucocorticoid   steroid   for the treatment of   as...
Monday, April 15, 2013

FDA Approves Sirturo to Treat Multi-Drug Resistant Tuberculosis

›
In continuation of my update on  bedaquiline ... Sirturo is being approved under the FDA’s accelerated approval program, which allows...
Saturday, April 13, 2013

FDA Approves Juxtapid - New Orphan Drug for Rare Cholesterol Disorder

›
In continuation of my update on  lomitapide .. US FDA, Juxtapid (lomitapide) to reduce low-density lipoprotein (LDL) cholesterol, tot...
Friday, April 12, 2013

FDA Approves Adasuve (loxapine) Inhalation Powder for the Acute Treatment of Agitation Associated with Schizophrenia or Bipo...

›
In continuation of my update on adasuve FDA Approves Adasuve (loxapine) Inhalation Powder for the Acute Treatment of Agitation Associa...
Thursday, April 11, 2013

Discovery could increase efficacy of promising cystic fibrosis drug

›
We know that,  Ivacaftor   (trade name   Kalydeco , developed as   VX-770 ) is a potentiator approved for patients with the G551D mutation...
Wednesday, April 10, 2013

Pain reliever shows anti-viral activity against flu

›
In continuation of my update on naproxen New influenza vaccines must be developed annually, because the surface proteins they target m...